Overview
- Editors:
-
-
Caroline J. Springer
-
Cancer Research UK Centre for Cancer Therapeutics at the Institute of Cancer Research, Sutton, UK
Access this book
Other ways to access
Table of contents (27 protocols)
-
-
- Ion Niculescu-Duvaz, Caroline J. Springer
Pages 1-27
-
-
- Kenneth Brooks Low, Martina Ittensohn, Xiang Luo, Li-Mou Zheng, Ivan King, John M. Pawelek et al.
Pages 47-59
-
- Masato Yamamoto, David T. Curiel
Pages 61-70
-
- Gunnel Halldén, Stephen H. Thorne, Jingping Yang, David H. Kirn
Pages 71-90
-
-
-
- Richard Brokx, Jean Gariépy
Pages 139-160
-
- Dan Niculescu-Duvaz, Ion Niculescu-Duvaz, Caroline J. Springer
Pages 161-202
-
- E. Antonio Chiocca, David J. Waxman
Pages 203-222
-
- Kimberly V. Curlee, William B. Parker, Eric J. Sorscher
Pages 223-245
-
- Mary K. Danks, Philip M. Potter
Pages 247-262
-
- Alexandre Evrard, Joseph Ciccolini, Pierre Cuq, Jean-Paul Cano
Pages 263-278
-
- Silke Schepelmann, Robert Spooner, Frank Friedlos, Richard Marais
Pages 279-301
-
-
- Jean-Emmanuel Kurtz, Margaret E. Black
Pages 331-344
-
- Wolfgang Uckert, Brian Salmons, Christian Beltinger, Walter H. Günzburg, Thomas Kammertöns
Pages 345-352
-
- Shigeki Kuriyama, Hirohisa Tsujinoue, Hitoshi Yoshiji
Pages 353-369
-
- Gabi U. Dachs, Olga Greco, Gillian M. Tozer
Pages 371-387
About this book
Gene therapy has expanded rapidly over the last decade. The number of clinical trials reported by 2001 included 532 protocols and 3436 patients. Phase I trials predominate with 359 trials of 1774 patients versus Phase II (57 trials with 507 patients) and Phase III (3 trials of 251 patients). The disease overwhelmingly targeted by gene therapy is cancer: involving 331 trials with 2361 patients. Despite the somewhat disappointing results of clinical trials to date, gene therapy offers tremendous promise for the future of cancer therapy. The area of gene therapy is vast, and both malignant and nonmalignant cells can be targeted. Suicide Gene Therapy: Methods and Reviews covers gene therapy that targets malignant cells in a treatment that has become known as “suicide gene therapy. ” Basically, this approach uses the transduction of cancer cells with a gene for a foreign enzyme that, when expressed, is able to activate a nontoxic prodrug into a highly cytotoxic drug able to kill the cancer cell population. This is a major area in cancer gene therapy—in 2001 this technique was represented by 52 clinical protocols with a total of 567 patients. Additional trials used multiple gene therapy protocols that also involved suicide gene therapy (83 with 497 patients), indicating that the interest in this area is considerable. Suicide Gene Therapy: Methods and Reviews aims to cover comprehensively, both in theoretical and practical terms, the rapidly evolving area of suicide gene therapy for cancer.
Reviews
"This is a good book for those working in the area of suicide gene therapy that can serve both as a reference to senior investigators as well as a primer to new lab members and researchers outside the field who are trying to get a flavor of the state of the field."-Doody's Health Sciences Book Review Journal
"...an extensive review of the theoretical background of suicide gene therapy that covers all major aspects..." - ChemBioChem
"Authoritative and up-to-date...provides the experimental means to advance its future development and therapeutic applications." - Anticancer Research
Editors and Affiliations
-
Cancer Research UK Centre for Cancer Therapeutics at the Institute of Cancer Research, Sutton, UK
Caroline J. Springer
